Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
- Previous Close
51.60 - Open
51.60 - Bid --
- Ask --
- Day's Range
51.60 - 51.60 - 52 Week Range
40.93 - 51.98 - Volume
2 - Avg. Volume
0 - Market Cap (intraday)
11.564B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
26.06 - EPS (TTM)
1.98 - Earnings Date --
- Forward Dividend & Yield 1.37 (2.65%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
--
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
www.recordati.com4,455
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RCDTF
Performance Overview: RCDTF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RCDTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RCDTF
Valuation Measures
Market Cap
10.77B
Enterprise Value
12.47B
Trailing P/E
26.02
Forward P/E
16.78
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.86
Price/Book (mrq)
5.92
Enterprise Value/Revenue
5.99
Enterprise Value/EBITDA
17.61
Financial Highlights
Profitability and Income Statement
Profit Margin
18.69%
Return on Assets (ttm)
9.54%
Return on Equity (ttm)
24.08%
Revenue (ttm)
2.08B
Net Income Avi to Common (ttm)
389.21M
Diluted EPS (ttm)
1.98
Balance Sheet and Cash Flow
Total Cash (mrq)
221.81M
Total Debt/Equity (mrq)
108.45%
Levered Free Cash Flow (ttm)
32.58M
Company Insights: RCDTF
RCDTF does not have Company Insights